More great reporting from Max Bayer on the ongoing fallout from Bristol Myers' step back from cell therapy R&D

BIG story from Max Bayer about the latest in a series of major changes at Sanofi

Great interview by @AGKootenay and a reminder of how brutal the public markets can still be for biotechs

We're growing the Fierce Biotech team! The first position we’re adding is a staff writer. We’re seeking someone with a few years of experience, ideally with a background in biotech writing. 🔗 recruiting.ultipro.com/QUE1003QSTX/Jo…

Great story here from @AGKootenay: "Despite releasing clinical data that included positive phase 3 results, receiving a fast-track designation from the FDA and receiving $10 million in non-dilutive funding, Vaxxinity’s shares still plummeted from the original list price."

What were the smartest deals in biopharma over the last few years? The FierceBiotech team run down some of our favs👀 fiercebiotech.com/biotech/smarte…

I noticed J&J had removed its Addex-partnered epilepsy drug from its pipeline. Turns out the Big Pharma had lost faith after April's phase 2 fail fiercebiotech.com/biotech/jj-dro…

Our recently announced partnership with GSK will develop a portfolio of entirely new medicines and vaccines to address unmet needs initially focused in respiratory and immunology. For more, read this FierceBiotech piece by James Waldron: fiercebiotech.com/biotech/gsk-be…

.FierceBiotech editor @GabrielleMasso9 was interviewed on the NYSE floor this morning! She shared insights on Fierce Biotech's Fierce 15 this year, the use of AI and other trends in the biotech market. Her segment starts at the 40:00 mark

Looks like Bayer's Juergen Eckhardt was right when he told Fierce in June that he wouldn't let the company's restructuring affect their push for oncology innovation fiercebiotech.com/biotech/bayer-…

Sanofi’s tolebrutinib failed 2 out of 3 phase 3 MS trials that read out this morning, but the pharma is still planning an FDA filing fiercebiotech.com/biotech/sanofi…

Sanofi's head of R&D told me the company will engage with the FDA “as soon as possible” to discuss filing for approval in non-relapsing secondary progressive MS

This morning sees another 2 biotechs joining the steady trickle of IPOs. Upstream has upsized its offering while CAMP4 has rebalanced its own $UBP $CAMP fiercebiotech.com/biotech/upstre…

At LSX in April, Gateway Labs' Julie Gilmore told me they planned to "go to geographies where we think we can make a difference.” Now it turns out one of those will be the UK... fiercebiotech.com/biotech/lilly-…

Today's news throws a spanner in two programs that CEO John Jacobs had been pointing to as potential growth drivers for the company fiercebiotech.com/biotech/fda-pu…

While the in vivo program is taking center stage, Editas Medicine told me work on reni-cel is not being halted, with a “substantive clinical data set” lined up for #ASH24

The KarXT crown looks secure in Bristol Myers' hands for a while at least

My dispatch from Day 1 of Jefferies 2024 - where everyone is now making the comparison with JPM (including the bad weather)

For this week's FierceBiotech podcast, I caught up with Novo Nordisk's Marcus Schindler to talk about the future of GLP-1s and the lessons he's learned as Chief Scientific Officer fiercepharma.com/pharma/novo-no…

Interesting to hear GSK CEO Emma Walmsley say that Big Pharma should "run towards" conversations about vaccine efficacy as the new U.S. admin approaches. My initial writeup of the #JPM2025 session is here... fiercebiotech.com/biotech/jpm25-…